Hologic (NSDQ:HOLX) posted second-quarter results today that trailed the consensus forecast, but the company forecasts a strong third quarter fueled by robust COVID-19 test revenue. The Marlborough, Mass.-based company posted profits of $1.09 billion, or $2.38 per share, on sales of $1.54 billion for the three months ended March 27, 2020. Sales growth in the […]
Diagenode
Hologic acquires molecular diagnostic company for $159M
Hologic today announced that it acquired molecular diagnostic company Diagenode for $159 million. Through the deal, Hologic will pay $159 million, subject to working capital and other customary closing adjustments. European Diagenode develops molecular diagnostic assays and epigenetic products. It has more than 30 real-time PCR tests that are CE-marked to detect bacteria, parasites and […]
